CoChat

NITRIC OXIDE IN ATHEROSCLEROSIS: VASCULAR PROTECTOR OR VILLAIN?

Dusting, Gregory J., Fennessy, Paul, Yin, Zhan‐Li, Gurevich, Vladimir · 1998 · Clinical and Experimental Pharmacology and Physiology
Cited by 54

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

SUMMARY: 1. Nitric oxide (NO) has important roles in physiological vasodilatation, cytotoxicity and vascular disease. Nitric oxide and prostacyclin (PGI2), both released from the endothelium, act synergistically to inhibit platelet aggregation and adhesion. These autacoids also inhibit the adhesion and migration of leucocytes and, in some arteries, they synergize in terms of vasodilatation. 2. The development of atherosclerosis and hyperlipaemia per se is accompanied by impairment of endothelium‐dependent vasodilatation. 3. Atherosclerosis is associated with marked changes in the activity of isoforms of NO synthase (NOS) in the artery wall, including increased expression of the NOS2 (inducible) isoform in complex human lesions as well as in the neointima of experimental animal models. 4. Failure of NO release from the endothelium with normal physiological stimuli, which has been attributed to a defect in the operation of the endothelial NOS (NOS3), provides conditions propitious for leucocyte adhesion, vasospasm, thrombosis and, in addition, may promote increased proliferation of intimal cells. 5. Nitric oxide and superoxide anions generated by inflammatory cells in atherosclerosis react to form cytodestructive per‐oxynitrite radicals, potentially causing injury to the endothelium and myocytes, and this may be a factor in apoptosis of cells leading to plaque rupture. 6. We have been able to reverse these NO defects with therapeutic agents, including angiotensin‐converting enzyme inhibitors, antagonists of platelet‐activating factor and NO donor compounds, all offering promise in protecting against some manifestations of vascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1681.1998.tb02298.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 54

Metadata

Authors
Dusting, G. J., Fennessy, P., Yin, Z., & Gurevich, V.
Venue
Clinical and Experimental Pharmacology and Physiology
Publisher
Wiley
Published
1998-11
Volume
25
Issue
S1
Pages
S34-41
ISSN
  • 0305-1870 (ISSN-L)
  • 1440-1681
OpenAlex
W2136078327
Cited by
54
References
6
FWCI
1.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NITRIC OXIDE IN ATHEROSCLEROSIS: VASCULAR PROTECTOR OR VILLAIN? https://app.cochat.ai/papers/10.1111/j.1440-1681.1998.tb02298.x
The paper
Dusting, G. J., Fennessy, P., Yin, Z., & Gurevich, V. (1998). NITRIC OXIDE IN ATHEROSCLEROSIS: VASCULAR PROTECTOR OR VILLAIN? Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/j.1440-1681.1998.tb02298.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.